Advertisement

Topics

Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit

07:27 EDT 14 Jun 2019 | SCRIP

Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of...

      

Related Stories

 

Original Article: Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit

NEXT ARTICLE

More From BioPortfolio on "Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...